Ergomed, a UK provider of specialised services to the pharmaceutical industry in addition to drug development, has appointed Andrew Mackie as Chief Business Officer. He has also joined the UK company's Board as Executive Director.
Mackie has more than 25 years of industry experience in pre-clinical research, clinical development and business development, having held a number of senior R&D roles in pharmaceutical (Lilly, Novartis, Sanofi), service (MDS), and biotech companies (Antisoma). He joins Ergomed from Eli Lilly where he worked for the Business Development team. Prior to this, he was Head of Life Sciences at IP Group.
After ten years in R&D, Mackie joined the UK biotech sector in 1997 at Antisoma, an oncology specialist. He established the clinical development department and transitioned new molecules into development and later managed the company’s strategic alliance with F Hoffman-La Roche and in-licensed new drug leads through partnerships and acquisitions.
Ergomed's Chief Executive Miroslav Reljanovic said: 'Over the past ten years, Andrew has worked with Ergomed as a consultant, and has been instrumental in developing the co-development business model, acting as lead negotiator on the partnerships signed to date. His successful track record in drug development and dealmaking not only strengthens our capabilities as we continue to advance our co-development pipeline but also ensures we have the right team in place as we look to expand through organic growth and acquisitions.'
